Drug manufacturer Amaran Biotechnology Inc (潤雅生技) yesterday said it is to invest NT$1 billion (US$33.41 million) to build a factory and a research center at Hsinchu Biomedical Science Park (新竹生醫園區) to conduct clinical trials and manufacture drugs developed by OBI Pharma Inc (台灣浩鼎).
The new facilities are set to become operational in the first quarter of next year, the Taipei-based Amaran said.
The factory will produce botulinum toxin type A biosimilar, which is commonly known as Botox and widely used in cosmetic surgery, along with other generic protein drugs, according to the company.
Botox has become very popular for reducing wrinkles and rejuvenating the aging face. It not only has applications in the cosmetics industry but can be used for drugs to treat migraine, squints, severe underarm sweating and dystonia -- sustained muscle contractions that cause twisting and repetitive movements or abnormal postures, according to Amaran.
The company said its new facilities will be the first plant in the nation to be constructed under level 3 biosafety conditions.
The biosafety level 3 is the second-highest on a scale of four, because a high safety level is required for facilities that manufacture Botox in order to limit contamination of the work environment and the surrounding community.
The global market for Botox in 2010 was US$2 billion and it is forecast to grow to US$4.3 billion in 2018, Amaran said, adding that it is the only company in Taiwan that can develop and manufacture that particular type of botulinum toxin.
The research center will be responsible for conducting clinical trials of generic protein drugs developed by Amaran’s partner, OBI Pharma, it said.
Amaran was set up in 2010 as a joint investment between OBI Pharma chairman Michael Chang (張念慈) and Samuel Yin (尹衍樑), the chairman of Ruentex Group (潤泰集團), a business with interests ranging from textiles and construction to retail.
“The reason why Amaran was formed is because we wanted to minimize our risks by letting OBI Pharma focus on the research and development of new drugs, while Amaran is responsible for conducting clinical trials and drug manufacturing,” an OBI Pharma official who declined to be named said by telephone yesterday.
“If our OBI-822/821 drug — which is used to treat breast cancer — can pass the third stage of clinical trials in Taiwan, the new factory will manufacture the drug for us,” she said.
Amaran is also expected to receive investment from Taishin Financial Holding Co (台新金控) chairman Thomas Wu (吳東亮), who attended college with Chang, after Amaran implements a capital enhancement initiative to strengthen its financial structure, which has a paid-in capital of NT$300 million (US$10 million).
Amaran did not give a timeline for the capital enhancement nor the amount that Wu was to invest in the company.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is